Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Registrational study of derazantinib in patients with second-line intrahepatic cholangiocarcinoma

Next Previous
Trial Profile

Registrational study of derazantinib in patients with second-line intrahepatic cholangiocarcinoma

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Derazantinib (Primary)
  • Indications Cholangiocarcinoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Sinovant Sciences

Most Recent Events

  • 07 Jun 2019 According to an ArQule media release, this trial ill be conducted in in collaboration with Basilea and Sinovant.
  • 30 Apr 2019 New trial record
  • 28 Apr 2019 According to a Sinovant Sciences media release, the company announced that its Clinical Trial Application for derazantinib has been accepted by the Center for Drug Evaluation at the China National Medical Products Administration, enabling the initiation of a registrational clinical trial in the second half of 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top